Skip to main content

Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets the RAS family of proteins. Catch up on the amazing progress scientists have made in targeting RAS by reading the AACR blog’s extensive coverage of the field, from the discovery of RAS as an oncogene to the development of drugs targeting this once-elusive protein and the new advances on the horizon.

The post Breaking News: Daraxonrasib Approved for Pancreatic Cancer appeared first on American Association for Cancer Research (AACR).

Source: Oncology

Read More